Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs ACTONEL WITH CALCIUM (COPACKAGED)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.
Mild to moderate pain,Fever
Treatment and prevention of postmenopausal osteoporosis,Treatment of glucocorticoid-induced osteoporosis,Treatment of Paget's disease of bone
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Terminal elimination half-life of risedronate is approximately 20 hours for the 5 mg daily dose and 480 hours for the 35 mg weekly dose due to prolonged retention in bone; clinically, the drug accumulates in bone and is slowly released.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Risedronate is not metabolized and is eliminated unchanged primarily via renal excretion.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Risedronate is eliminated primarily via renal excretion, with approximately 50% of an absorbed dose excreted unchanged in urine. Unabsorbed drug is eliminated in feces. Total clearance is about 100 m L/min.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Risedronate is approximately 24% bound to plasma proteins.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Volume of distribution for risedronate is approximately 6.3 L/kg, indicating extensive distribution into bone and other tissues.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Oral bioavailability of risedronate is low, averaging 0.63% for the 5 mg tablet when taken under fasting conditions; administration with food reduces bioavailability significantly (by up to 50%).
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-49 m L/min: no dose adjustment needed. For Cr Cl ≥50 m L/min: no adjustment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Not indicated for use in pediatric patients. Safety and efficacy not established.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
No specific dose adjustment required. Caution in patients with decreased renal function; monitor renal status. Increased risk of hypocalcemia if calcium intake inadequate.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
None
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypocalcemia must be corrected before therapy,Severe renal impairment (Cr Cl <30 m L/min) is not recommended,Esophageal irritation: instruct patients to swallow with full glass of water and not to lie down for 30 minutes,Osteonecrosis of the jaw (rare, mainly with cancer doses),Atypical femur fractures (rare, with long-term use),Avoid concomitant use with other bisphosphonates
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Hypocalcemia,Severe renal impairment (Cr Cl <30 m L/min),Inability to sit or stand upright for at least 30 minutes,Hypersensitivity to risedronate or any component,Use in patients with esophageal abnormalities that delay emptying (e.g., stricture, achalasia)
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Risedronate absorption is significantly reduced by food, especially dairy products, calcium-rich foods, and beverages other than plain water. Avoid all food, beverages (except plain water), and other medications for at least 30 minutes after the dose. Calcium supplement should be taken with a meal to enhance absorption.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during pregnancy. No adequate studies in pregnant women; use only if clearly needed. Calcium carbonate: Generally considered safe but excessive doses may cause hypercalcemia-related fetal risks. First trimester: Limited data, avoid if possible. Second/third trimester: Use only if maternal benefit outweighs fetal risk.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Risedronate: Unknown if excreted in human milk; not recommended due to potential for bone growth inhibition. Calcium: Excreted in breast milk at normal maternal intake levels; no adverse effects reported. M/P ratio: Unknown for risedronate; calcium M/P ratio approximately 1.1.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Risedronate: No specific dose adjustments are recommended in pregnancy due to lack of data; generally avoided. Calcium: No dose adjustment needed; maintain recommended daily intake (1000-1300 mg/day). Pregnancy may increase calcium absorption but no dose change required for supplementation.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Actonel (risedronate) with calcium (copackaged) is used for osteoporosis. Administer risedronate on an empty stomach with plain water, at least 30 minutes before first food, drink, or other medications. Wait at least 30 minutes after risedronate before taking the calcium supplement. Calcium can interfere with risedronate absorption.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Take the risedronate tablet first thing in the morning, at least 30 minutes before eating or drinking anything except plain water.,Swallow the risedronate tablet whole with a full glass of plain water (6-8 oz). Do not crush, chew, or suck the tablet.,Do not lie down for at least 30 minutes after taking risedronate to reduce risk of esophageal irritation.,After taking risedronate, wait at least 30 minutes before taking the calcium supplement provided in the copack.,Take the calcium supplement with food or after a meal to improve absorption and reduce stomach upset.,Report any symptoms of esophageal problems (difficulty or pain on swallowing, heartburn, or retrosternal pain) or jaw pain (possible osteonecrosis of the jaw).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs ACTONEL WITH CALCIUM (COPACKAGED), answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. ACTONEL WITH CALCIUM (COPACKAGED) is a Bisphosphonate and Calcium Supplement that works by ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and ACTONEL WITH CALCIUM (COPACKAGED) depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of ACTONEL WITH CALCIUM (COPACKAGED) is: Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and ACTONEL WITH CALCIUM (COPACKAGED) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. ACTONEL WITH CALCIUM (COPACKAGED) is classified as Category C. Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.